DexCom, Inc. $DXCM Shares Bought by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. lifted its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 1.1% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 973,141 shares of the medical device company’s stock after buying an additional 10,307 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in DexCom were worth $65,483,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the business. SWS Partners purchased a new stake in shares of DexCom during the 2nd quarter worth about $1,661,000. Baader Bank Aktiengesellschaft acquired a new position in DexCom during the second quarter valued at approximately $393,000. Jennison Associates LLC grew its stake in DexCom by 9.4% during the second quarter. Jennison Associates LLC now owns 11,517,546 shares of the medical device company’s stock worth $1,005,367,000 after buying an additional 994,300 shares during the period. Assenagon Asset Management S.A. increased its position in shares of DexCom by 85.7% in the second quarter. Assenagon Asset Management S.A. now owns 1,208,255 shares of the medical device company’s stock worth $105,469,000 after acquiring an additional 557,576 shares in the last quarter. Finally, Mn Services Vermogensbeheer B.V. raised its stake in shares of DexCom by 4.9% in the 2nd quarter. Mn Services Vermogensbeheer B.V. now owns 146,600 shares of the medical device company’s stock valued at $12,797,000 after acquiring an additional 6,800 shares during the period. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

DexCom Trading Down 0.8%

NASDAQ:DXCM opened at $69.70 on Thursday. The stock has a market cap of $27.18 billion, a price-to-earnings ratio of 38.72, a price-to-earnings-growth ratio of 1.27 and a beta of 1.48. DexCom, Inc. has a one year low of $54.11 and a one year high of $93.25. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.38 and a current ratio of 1.56. The business’s 50-day simple moving average is $64.52 and its 200 day simple moving average is $71.78.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.04. The company had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.18 billion. DexCom had a return on equity of 30.65% and a net margin of 15.96%.DexCom’s quarterly revenue was up 21.6% on a year-over-year basis. During the same period in the prior year, the company posted $0.45 EPS. As a group, sell-side analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently weighed in on DXCM. Morgan Stanley restated an “overweight” rating on shares of DexCom in a report on Monday. Leerink Partners restated an “outperform” rating and set a $92.00 price objective on shares of DexCom in a research note on Tuesday, December 16th. Royal Bank Of Canada lowered their target price on DexCom from $100.00 to $85.00 and set an “outperform” rating for the company in a research note on Friday, October 31st. UBS Group dropped their target price on DexCom from $106.00 to $95.00 and set a “buy” rating on the stock in a report on Monday, November 3rd. Finally, BTIG Research decreased their price target on DexCom from $109.00 to $85.00 and set a “buy” rating for the company in a report on Friday, October 31st. Three analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $86.30.

Insider Buying and Selling at DexCom

In other news, Director Richard Alexander Collins sold 3,948 shares of the stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $55.17, for a total transaction of $217,811.16. Following the transaction, the director owned 37,994 shares of the company’s stock, valued at approximately $2,096,128.98. This trade represents a 9.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Jacob Steven Leach acquired 18,200 shares of the stock in a transaction that occurred on Monday, November 10th. The stock was purchased at an average cost of $55.04 per share, with a total value of $1,001,728.00. Following the completion of the acquisition, the chief operating officer owned 331,697 shares of the company’s stock, valued at $18,256,602.88. The trade was a 5.81% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have sold 7,866 shares of company stock worth $448,177 in the last ninety days. 0.32% of the stock is owned by insiders.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.